Clinical trial
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in Adolescent and Adult Patients With Hemophilia A.
NCT04456387 is registered in ClinicalTrials.gov with Zhengzhou Gensciences Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in Adolescent and Adult Patients With Hemophilia A.
- Lead sponsor
- Zhengzhou Gensciences Inc
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 15, 2020
- Completion date
- September 30, 2021
- Enrollment
- 119 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.